Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

ABSTRACT: The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) < 15 ml min^-1 1.73 m^-2, persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence i

SUBMITTER: Colhoun HM 

PROVIDER: S-EPMC11271413 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature